Shares of Enovis Corporation (ENOV) surged 5.84% in pre-market trading on Thursday after the medical technology company reported better-than-expected second-quarter 2025 results and raised its full-year guidance. The strong performance was driven by robust sales growth, particularly in the company's Reconstructive segment.

Enovis announced Q2 revenue of $564.5 million, up 7% year-over-year and beating analyst estimates of $554.6 million. The company's adjusted earnings per share came in at $0.79, significantly higher than the consensus estimate of $0.72. The Reconstructive segment was a standout performer, with sales growing 11% on a reported basis. Enovis CEO Damien McDonald highlighted "continued execution in P&R and Recon, stable end markets, and encouraging momentum in new product introductions" as key drivers of the quarter's success.

Following the strong results, Enovis raised its full-year 2025 outlook. The company now expects revenue between $2.245 billion and $2.275 billion, up from the previous guidance of $2.220-2.250 billion. Adjusted earnings per share guidance was also increased to $3.05-$3.20, compared to the prior range of $2.95-$3.10. The improved outlook reflects management's confidence in the company's growth trajectory and operational performance for the remainder of the year.